Compare GAU & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAU | INDP |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.6M | 438.4M |
| IPO Year | 2006 | 2021 |
| Metric | GAU | INDP |
|---|---|---|
| Price | $2.47 | $3.35 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.85 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 329.8K |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $99.00 | N/A |
| Revenue Next Year | $39.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $0.92 |
| 52 Week High | $3.62 | $5.96 |
| Indicator | GAU | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 56.71 |
| Support Level | $2.40 | $2.05 |
| Resistance Level | $2.75 | $3.84 |
| Average True Range (ATR) | 0.13 | 0.31 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 99.10 | 74.71 |
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.